| id | Study | Lib. in paper | Exposition period | Study type |
Control type |
Tags | OR 95%CI | x1/n1 x0/n0 | no cases | no exposed | ROB | Ref. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| S17049 R76881 |
Suarez (Controls unexposed, discontinuers), 2022 | Intellectual disability - ≥ 2 dates with ICD-9 Dx 317, 318.x, 319 - At ≥ 2 years of age | 2nd and/or 3rd trimester | retrospective cohort (claims database) | unexposed, sick | Adjustment: Yes Monotherapy: no or not specified Unexposed sick: recent illness/treatment (during or juste before pregnancy or treatment stopped in view of pregnancy) | 0.95 [0.64;1.40] | 170/115,060 56/38,038 | 226 | 115,060 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S17050 R76882 |
Suarez (Controls unexposed, general pop), 2022 | Intellectual disability - ≥ 2 dates with ICD-9 Dx 317, 318.x, 319 - At ≥ 2 years of age | 2nd and/or 3rd trimester | retrospective cohort (claims database) | unexposed (general population or NOS) excluded | Adjustment: Yes Monotherapy: no or not specified |
0.97 [0.79;1.20] excluded (control group) |
170/115,110 2,950/3,000,907 | 3,120 | 115,110 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S10002 R53813 |
Ames (Controls unexposed, disease free), 2021 | Developmental delays or disorders (identified from clinical or educational settings) and with score <11 on the SCQ or score >=11 but did not meet study criteria for ASD after the in-person assessment (presence or absence of co-occurring ID defined by MSEL composite standard scores <=70) (Age NOS). | during pregnancy (anytime or not specified) | case control | unexposed, disease free excluded | Adjustment: Yes Monotherapy: no or not specified |
1.92 [1.43;2.57] excluded (control group) |
145/226 1,605/3,195 | 1,750 | 226 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S10003 R53814 |
Ames (Controls unexposed, sick), 2021 | Developmental delays or disorders (identified from clinical or educational settings) and with score <11 on the SCQ or score >=11 but did not meet study criteria for ASD after the in-person assessment (presence or absence of co-occurring ID defined by MSEL composite standard scores <=70) (Age NOS). | during pregnancy (anytime or not specified) | case control | unexposed, sick | Adjustment: Yes Monotherapy: no or not specified Unexposed sick: recent illness/treatment (during or juste before pregnancy or treatment stopped in view of pregnancy) | 1.38 [0.98;1.95] | 145/226 -/- | - | 226 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S482 R53820 |
Harrington, 2014 | Developmental delay (Vineland Adaptive Behavior Scales and Mullen Scales of Early Learning (composite score <=70 on either scale)) - Mean 3.7 years (2-5 years) | during pregnancy (anytime or not specified) | case control | unexposed (general population or NOS) | Adjustment: Yes Matched Monotherapy: no or not specified | 1.62 [0.59;4.42] | 8/19 146/455 | 154 | 19 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S8046 R53815 |
Batton, 2013 | Mental Developmental Index/ Cognitive Composite score on the Bayley Scales of Infant Development (BSID) at 36 months | during pregnancy (anytime or not specified) | retrospective cohort | unexposed, disease free | Adjustment: No extrapolated (cont. endpoint) Monotherapy: SSRI only | 0.66 [0.18;2.43] | -/15 -/15 | - | 15 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S7051 R53816 |
Nulman (Controls unexposed, disease free), 2012 | Full-scale IQ (The Wechsler Preschool and Primary Scale of Intelligence– Third Edition) at 3-6 years | during pregnancy (anytime or not specified) | prospective cohort | unexposed, disease free excluded | Adjustment: No extrapolated (cont. endpoint) Monotherapy: SSRI only |
2.85 [1.49;5.47] excluded (control group) |
-/62 -/62 | - | 62 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S5377 R53817 |
Nulman (Controls unexposed, sick), 2012 | Full-scale IQ (The Wechsler Preschool and Primary Scale of Intelligence– Third Edition) at 3-6 years | during pregnancy (anytime or not specified) | prospective cohort | unexposed, sick | Adjustment: No extrapolated (cont. endpoint) Monotherapy: SSRI only Unexposed sick: intermediate history of illness/treatment (3-12 months before pregnancy) | 1.49 [0.77;2.90] | -/62 -/54 | - | 62 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S8013 R53818 |
Nulman - Fluoxetine (Controls exposed to TCA), 2002 | Global IQ with the McCarthy Scales of Children’s Abilities at 30 and 71 months of age | throughout pregnancy | prospective cohort | exposed to other treatment, sick excluded | Adjustment: No extrapolated (cont. endpoint) Monotherapy: SSRI only |
3.35 [0.60;18.67] excluded (control group) |
-/6 -/18 | - | 6 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S8014 R53819 |
Nulman - Fluoxetine (Controls unexposed, disease free), 2002 | Global IQ with the McCarthy Scales of Children’s Abilities at 30 and 71 months of age | throughout pregnancy | prospective cohort | unexposed, disease free | Adjustment: No extrapolated (cont. endpoint) Monotherapy: SSRI only | 3.79 [0.66;21.98] | -/6 -/16 | - | 6 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Total | 6 studies | 1.23 [0.97;1.56] | 380 | 115,388 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1: Controls unexposed, discontinuers; 2: Controls unexposed, sick; 3: Controls unexposed, sick; 4: Controls unexposed, disease free;
Asymetry test p-value = 0.5823 (by Egger's regression)
slope=0.0741 (0.2556); intercept=0.5348 (0.8950); t=0.5975; p=0.5823
excluded 8013, 7051, 10002, 17050